Saturday 17 October 2026
Export HAE’s income statement to Excel — free account
Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
118.28
3.01
−2.48%
Follow HAE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
14.17 | 21.96 | 27.76 | 36.59 |
P/S ratio |
1.75 | 2.84 | 1.99 | 2.52 | |
P/FCF ratio |
8.95 | 12.04 | 10.16 | 11.63 | |
P/Operating CF |
20.84 | 40.08 | 37.48 | 65.02 | |
P/B ratio |
2.73 | 4.11 | 3.34 | 4.06 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.22 | 3.27 | 2.72 | 3.22 | |
EV/EBITDA |
8.01 | 11.57 | 13.25 | 15.88 | |
EV/Operating CF |
10.18 | 12.71 | 12.39 | 13.25 | |
EV/FCF |
11.36 | 13.83 | 13.88 | 14.86 | |
Quick Ratio |
0.92 | 1.04 | 1.64 | 1.67 | |
Current Ratio |
1.64 | 1.75 | 2.95 | 3.08 | |
Net Debt/EBITDA |
7.03 | 5.79 | 226.86 | 11.18 | |
Debt/Assets |
37.69% | 36.93% | 50.90% | 49.43% | |
Debt/Equity |
1.08 | 1.01 | 1.53 | 1.40 | |
Asset Turnover |
0.53 | 0.53 | 0.55 | 0.56 | |
Operating CF/Net income |
2.88 | 2.09 | (3.52) | 1.59 | |
Capex/Depreciation |
(0.16) | (0.21) | (0.63) | (0.28) | |
Interest Coverage |
8.12 | 9.08 | (4.28) | 5.81 | |
Research and Development Expense of Revenue |
4.54% | 4.19% | 4.17% | 4.77% | |
Selling, General and Administrative Expense of Revenue |
31.05% | 32.20% | 34.92% | 35.05% | |
Intangible Assets out of Total Assets |
0.42 | 0.41 | 0.46 | 0.46 | |
Share Based Compensation of Revenue |
2.32% | 2.30% | 2.64% | 2.74% | |
Graham Net Nets |
(0.30) | (0.17) | (0.29) | (0.21) | |
Graham Number |
37.16 | 40.00 | 27.77 | 29.18 | |
Earnings Yield |
7.06% | 4.55% | 3.60% | 2.73% | |
Free Cash Flow Yield |
11.17% | 8.30% | 9.85% | 8.60% | |
Revenue per Share |
6.88 | 7.24 | 7.34 | 7.48 | |
Operating CF per Share |
2.34 | 2.00 | 1.50 | 1.15 | |
Capex per Share |
(0.10) | (0.13) | (0.36) | (0.17) | |
Free Cash Flow per Share |
2.24 | 1.87 | 1.14 | 0.98 | |
Cash per Share |
6.23 | 7.77 | 5.20 | 4.92 | |
Shareholders Equity per Share |
17.84 | 19.48 | 16.88 | 18.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.84 | 19.48 | 16.88 | 18.45 | |
Free Cash Flow |
106.43 | 87.65 | 53.81 | 44.65 | |
Working Capital |
351.36 | 403.81 | 552.28 | 547.60 | |
Capital Expenditures |
(4.90) | (5.92) | (17.13) | (7.67) | |
Net Current Asset Value |
(693.30) | (635.76) | (764.73) | (717.47) | |
EV/EBIT |
12.13 | 17.15 | 23.18 | 27.12 | |
Capex to Sales |
0.02 | 0.02 | 0.05 | 0.02 | |
Price to Operating Income |
9.56 | 14.94 | 16.97 | 21.22 | |
| Other line items | |||||
Average Receivables |
210.30 | 203.83 | 209.76 | 208.41 | |
Average Payables |
65.47 | 55.84 | 59.03 | 51.17 | |
Average Inventory |
359.16 | 340.40 | 335.76 | 333.63 | |
Average Assets |
2,483.69 | 2,511.08 | 2,423.44 | 2,413.75 | |
Average Common Equity |
864.01 | 909.16 | 808.58 | 859.70 |
Columns are period end dates